Carbinoxamine


Concise Prescribing Info
Indications/Uses
Allergic conditions.
Dosage/Direction for Use
Adult: PO As immediate-release tab/soln: 4-8 mg 3-4 times/day. As extended-release susp: 6-16 mg 12 hrly.
Administration
Should be taken with food.
Contraindications
Concomitant use w/ MAOIs. Childn <2 yr. Lactation.
Special Precautions
Patient w/ asthma, increased intraocular pressure, narrow angle glaucoma, hyperthyroidism, CV disease, HTN, stenosing peptic ulcer, prostatic hypertrophy, bladder neck and pyloroduodenal obstructions. Elderly. Pregnancy. Patient Counselling This drug may cause drowsiness and impaired mental or physical ability, if affected, do not drive or operate machinery.
Adverse Reactions
Urticaria, rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dry mouth, nose, and throat; epigastric distress, anorexia, nausea, vomiting, diarrhoea, constipation; hypotension, headache, palpitations, tachycardia, extrasystoles; fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paraesthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsion, sedation, drowsiness, dizziness, disturbed coordination; increased uric acid levels; chest tightness, wheezing, nasal stuffiness, thickening of bronchial secretions; urinary frequency, difficult urination, urinary retention, early menses; haemolytic anaemia, thrombocytopenia, agranulocytosis.
Drug Interactions
May increase the effect of other antihistamines, barbiturates, TCAs, and CNS depressants (e.g. hypnotics, sedatives, tranquilisers).
ATC Classification
R06AA08 - carbinoxamine ; Belongs to the class of aminoalkyl ethers used as systemic antihistamines.
Disclaimer: This information is independently developed by CIMS based on carbinoxamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in